• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

    24.50 +0.11 (+0.45%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,498,596
    Open 25.00
    Bid (Size) 24.50 (100)
    Ask (Size) 24.56 (100)
    Prev. Close 24.39
    Today's Range 24.21 - 25.48
    52wk Range 20.23 - 38.26
    Shares Outstanding 79,199,501
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
    From Pomerantz LLP
    Via GlobeNewswire

    Performance

    52-Week Range 36.0% below 52-week high
    24.50
    20.2352W Low 38.2652W High
    1 Week 3.8% below 1-week high
    23.441W Low 25.481W High

    Beam Therapeutics Inc. - Common Stock (BEAM) traded between $20.23 and $38.26 over the past 52 weeks and last traded at $24.50, 36.0% below its 52-week high. Over the past week it ranged between $23.44 and $25.48.

    Past 12 Months
    +1.1%
    -16.8%
    -30.6%
    +1.1%
    -9.7%
    -4.9%
    1W +$0.27
    1M -$4.96
    3M -$10.82
    6M +$0.27
    YTD -$2.64
    1Y -$1.25

    BEAM was -4.9% over the past year, +1.1% over six months, -9.7% year to date, +1.1% in the last week.

    12 Months vs Market
    BEAM
    -4.9%
    DIA
    +9.3%
    SPY
    +15.0%
    QQQ
    +24.3%
    IWM
    +14.5%

    Over the past 12 months BEAM returned -4.9% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +14.5%.

    Volume & Liquidity 0.76× 3-mo avg
    Today 1,498,596 3-mo avg 2.0M
    1W
    1.5M
    1M
    2.0M
    3M
    2.0M
    6M
    2.1M
    YTD
    2.1M
    1Y
    2.1M

    BEAM most recently traded 1,498,596 shares against a 3-month average daily volume of 2.0M.

    More News

    Read More
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
    Via The Motley Fool
    News headline image
    A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
    Via The Motley Fool
    News headline image
    Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
    Via The Motley Fool
    News headline image
    Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
    From Beam Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Beam Therapeutics Inc. - Common Stock publicly traded?
    Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Beam Therapeutics Inc. - Common Stock trade on?
    Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
    The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
    What is the current price of Beam Therapeutics Inc. - Common Stock?
    The current price of Beam Therapeutics Inc. - Common Stock is 24.50
    When was Beam Therapeutics Inc. - Common Stock last traded?
    The last trade of Beam Therapeutics Inc. - Common Stock was at 10/02/26 04:00 PM ET
    What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
    The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.94B
    How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
    Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.